Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients
- PDF / 827,316 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 83 Downloads / 156 Views
ORIGINAL ARTICLE
Risk factors for gemcitabine plus nab‑paclitaxel‑induced interstitial lung disease in pancreatic cancer patients Tsuyoshi Takeda1 · Takashi Sasaki1 · Koshiro Fukuda1 · Takafumi Mie1 · Takaaki Furukawa1 · Yuto Yamada1 · Akiyoshi Kasuga1 · Masato Matsuyama1 · Masato Ozaka1 · Naoki Sasahira1 Received: 30 June 2020 / Accepted: 29 October 2020 © Japan Society of Clinical Oncology 2020
Abstract Background Drug-induced interstitial lung disease (ILD) is one of the most serious adverse events with a high mortality rate and represents a serious clinical problem. However, gemcitabine plus nab-paclitaxel (GnP)-induced ILD in pancreatic cancer (PC) patients has not been thoroughly investigated. Therefore, we conducted this study to examine the clinical characteristics of GnP-induced ILD and identify risk factors for developing ILD. Methods We retrospectively investigated consecutive patients with PC who received GnP between January 2015 and April 2020. We compared the clinical characteristics and overall survival (OS) according to ILD occurrence and explored risk factors including ABO blood type for developing ILD. Results Of the 910 patients included in this study, ILD occurred in 20 patients (2.2%). PC patients who developed ILD had a significantly higher frequency of blood type B compared to those without ILD (42% vs. 22%, p ˂ 0.05). Other baseline characteristics including smoking history and current/previous lung disease were not different between the two groups. Median time from initiation of GnP to onset of ILD was 80 days. All patients recovered from ILD and OS was not significantly different according to ILD occurrence. Multivariate analysis revealed that blood type B was an independent risk factor for developing ILD. Conclusions We demonstrated that GnP-induced ILD occurred in 2.2% of PC patients with no mortality and OS did not differ according to ILD occurrence. Furthermore, we clarified that ABO blood type B was an independent risk factor for developing ILD in PC patients receiving GnP. Keywords Pancreatic cancer · Interstitial lung disease · Gemcitabine plus nab-paclitaxel · Blood type · Risk factor Abbreviations PC Pancreatic cancer GnP Gemcitabine plus nab-paclitaxel ECOG Eastern Cooperative Oncology Group PS Performance status
ILD Interstitial lung disease COPD Chronic obstructive pulmonary disease OS Overall survival TTF Time to treatment failure
* Takashi Sasaki sasakit‑[email protected]
Akiyoshi Kasuga [email protected]
Tsuyoshi Takeda [email protected]
Masato Matsuyama [email protected]
Koshiro Fukuda [email protected]
Masato Ozaka [email protected]
Takafumi Mie [email protected]
Naoki Sasahira [email protected]
Takaaki Furukawa [email protected]
1
Yuto Yamada [email protected]
Department of Hepato‑Biliary‑Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3‑8‑31, Ariake, Koto, Tokyo 135‑8550, Japan
13
Vol.:(0123456789)
OR Odds ratio C
Data Loading...
